SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 61,800 shares, an increase of 64.4% from the February 13th total of 37,600 shares. Based on an average daily trading volume, of 74,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On SOPHiA GENETICS

Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its stake in SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock valued at $68,000 after buying an additional 4,115 shares in the last quarter. Silverberg Bernstein Capital Management LLC bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $70,000. Green Alpha Advisors LLC increased its holdings in shares of SOPHiA GENETICS by 119.3% in the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after acquiring an additional 25,686 shares during the last quarter. Federated Hermes Inc. raised its position in shares of SOPHiA GENETICS by 40.5% during the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after acquiring an additional 28,819 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in SOPHiA GENETICS by 6.5% during the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock worth $2,180,000 after purchasing an additional 42,689 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $3.22 on Monday. The firm has a market cap of $214.73 million, a price-to-earnings ratio of -2.95 and a beta of 1.01. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $3.58 and its two-hundred day moving average is $3.53. SOPHiA GENETICS has a 52-week low of $2.70 and a 52-week high of $6.28.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The firm had revenue of $17.73 million for the quarter, compared to analysts’ expectations of $17.71 million. Analysts forecast that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. BTIG Research set a $5.00 price target on SOPHiA GENETICS in a research report on Thursday, March 6th. Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 target price on the stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.